Duke Energy Corp vs Edwards Lifesciences Corporation Common Stock — how do they compare? Duke Energy Corp trades at $116.51 (market cap $90.06B), while Edwards Lifesciences Corporation Common Stock trades at $84.25 (market cap $49.44B). The key difference: Duke Energy Corp is the larger of the two by market cap, and Duke Energy Corp pays a 3.76% dividend while Edwards Lifesciences Corporation Common Stock pays none. Which is the better fit depends on your goals.
| DUK | EW | |
|---|---|---|
Market Cap | $90.06B | $49.44B |
Volume | 3,988,081 | 3,508,027 |
Sector | Utilities | Health |
52-Week High | $133.46 | $95.18 |
52-Week Low | $113.23 | $72.65 |
Typical Hold Time | 74 Days | — |
Enterprise Value | $182.56B | $45.90B |
Dividend Yield | 3.76% | — |
Signals from Pluang's Aura AI — not financial advice
Duke Energy (DUK) trades at $116.84, up 1.02% on the day, with a bearish technical signal but strong fundamentals including consistent earnings beats and a 15.78% net income margin. Recent news highlights dividend stability and data center growth opportunities, though rising Treasury yields pressure utility stocks. The company maintains solid cash flow from operations of $12.33B in 2025, supporting its dividend payments.
DUK offers a balanced outlook with a consensus price target of $135.33, implying upside, but faces risks from high debt levels and interest rate sensitivity. Earnings growth and data center demand are key catalysts, while investor sentiment is mixed amid macroeconomic headwinds.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →Edwards Lifesciences develops medical technologies for structural heart disease. Its products include transcatheter aortic-valve replacement, mitral and tricuspid therapies, and surgical structural-heart technologies.
Read more on EW →